Healthcare royalty funds

Healthcare royalty funds operate in a niche space, focusing on acquiring royalty streams from pharmaceutical products, medical devices, or other healthcare-related intellectual property. Differentiating between successful platforms and underperformers often comes down to understanding their strategies and execution capabilities. Here's what you should consider:

Key Differentiators for Successful Healthcare Royalty Funds

1. Portfolio Diversification:

   • Strong funds typically diversify their royalty streams across multiple products, therapeutic areas, and geographies to mitigate risk.
   • Funds overly reliant on a single blockbuster drug or a narrow therapeutic area may face significant volatility.

2. Due Diligence and Asset Selection:

   • Top-performing funds conduct rigorous due diligence, focusing on the stability and growth potential of the royalty streams.
   • They assess factors like patent life, competitive landscape, regulatory risks, and market demand for the underlying products.

3. Management Expertise:

   • Funds with experienced teams, particularly those with deep healthcare and pharmaceutical backgrounds, tend to make better investment decisions.
   • Look for platforms with a track record of identifying high-quality assets and navigating complex healthcare markets.

4. Capital Deployment and IRR Targets:

   • Successful funds often have disciplined capital deployment strategies, targeting assets with attractive internal rates of return (IRR) and stable cash flows.
   • Funds with hurdle rates as low as ~12% IRR are common in healthcare, but the ability to exceed these benchmarks consistently is a sign of a strong platform.

5. Regulatory and Market Insight:

   • Funds that stay ahead of regulatory changes and market trends (e.g., generic competition, pricing pressures) are better positioned to protect and grow their investments.

Funds to Avoid

• Poor Performance History: Funds with consistent underperformance (e.g., 6% returns) may lack the expertise or strategy to compete effectively.
• Overleveraged Platforms: Funds that rely heavily on debt to acquire royalty streams may struggle during downturns or if cash flows from royalties decline.
• Limited Fundraising Ability: Funds unable to raise additional capital or facing potential wind-downs are risky, as they may lack the resources to support or expand their portfolios.

Notable Players

• Blackstone (BX) has been mentioned as a successful player in this space, leveraging its scale and expertise to identify high-quality assets.
• Other funds with strong reputations often have robust healthcare-focused teams and a history of delivering competitive returns.

Final Thoughts

When evaluating healthcare royalty funds, focus on their qualitative strategies, such as diversification, due diligence, and management expertise. Avoid platforms with poor performance, high leverage, or limited fundraising capabilities. If you're considering specific funds, digging into their historical performance and portfolio composition will provide valuable insights.

Sources: Is Private Equity a Low-IQ Approach to Finance?, Healthcare Overview... Part 1?, Healthcare Overview... Part 1?